SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk - Summary - MDSpire

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

  • By

  • Andrea Surnit

  • June 9, 2026

Share

Objective:

To investigate the association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and the incidence of kidney cancer in patients with type 2 diabetes, highlighting its significance in diabetes management.

Key Findings:
  • SGLT2 inhibitor users had 38 kidney cancer events (incidence rate of 18.9 per 100,000 person-years) compared to 64 events in DPP-4 users (30.8 per 100,000 person-years), totaling 102 events.
  • SGLT2 inhibitor use was associated with a 40% lower hazard of kidney cancer (hazard ratio 0.60, 95% CI 0.40 to 0.89).
  • The association remained consistent across various subgroups and sensitivity analyses.
Interpretation:

The findings suggest a potential association between SGLT2 inhibitor use and lower kidney cancer risk, with implications for clinical practice, but further validation is needed.

Limitations:
  • Observational design may introduce residual confounding.
  • Short follow-up period may not capture all kidney cancer cases.
  • Lack of tumor pathology data prevents subtype analysis.
  • Generalizability may be limited to Korean patients.
Conclusion:

The study indicates a lower incidence of kidney cancer among SGLT2 inhibitor users compared to DPP-4 inhibitor users, warranting further research to confirm these findings.

Original Source(s)

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

  • by Andrea Surnit

  • June 9, 2026

Related Content

Birthweight, Childhood BMI: What Drives the Link?

Mendelian randomization analyses linked higher birthweight with greater mid-childhood height but the connection could reflect genetic factors related to skeletal growth.

Hybrid deep feature and machine learning framework for classification of thyroid nodules in ultrasound images

NHS-Galleri Linked to Delays

Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.